Benitec Biopharma Inc.’s SEC filings document a Nasdaq-listed clinical-stage biotechnology company developing genetic medicines, including the BB-301 program for OPMD-related dysphagia. Its reports and current filings cover operating and financial results, clinical-development updates, Regulation FD disclosures, and capital-structure information for its common stock.
The company’s proxy and governance filings describe annual meeting matters, board composition, director compensation, equity incentive arrangements, and related corporate-governance disclosures. Form 8-K filings also record material events such as financial-result releases, operational updates, clinical-study disclosures, and director appointments.
Benitec Biopharma Inc. is seeking stockholder votes at its virtual December 3, 2026 annual meeting on three Class I director seats, ratification of Ernst & Young LLP as auditor for the year ending June 30, 2027, and a non-binding advisory vote on named executive compensation. The director nominees are Sharon Mates, Kishen Mehta and Edward Smith, whose terms would run until the 2029 annual meeting if elected.
As of October 13, 2026, 34,889,313 common shares were issued and outstanding. The count excludes unexercised pre-funded warrants to purchase up to 14,604,643 shares; warrant holders have no voting rights until exercise, which is subject to beneficial-ownership limits. The beneficial-ownership table lists Montanova Capital-affiliated entities at 17,952,309 shares, or 43.48%, including warrant shares subject to those limits.
For fiscal 2026, reported total compensation was $6,516,319 for CEO Dr. Jerel A. Banks, $3,167,437 for CFO Megan Boston and $6,706,443 for COO Sophie Mukadam. These totals include grant-date fair values of stock and option awards, which do not necessarily reflect amounts ultimately recognized by the executives.
Benitec Biopharma Inc. said the FDA requested additional available data for BB-301 as discussions continue on an open-label, single-arm pivotal study. The requested data include information from Benitec’s OPMD Natural History Study. The FDA agreed to review relevant information on a timeline that would allow Benitec to confirm the final study design in the first quarter of 2027.
Benitec says the pivotal study remains on track to begin in mid-2027, with patient enrollment planned for mid-2027. At the European Society of Gene and Cell Therapy Annual Congress in Hamburg, October 27–30, 2026, the company plans to present 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients in its ongoing Phase 1b/2a study.
Benitec Biopharma Inc. engaged Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027. EY completed its client acceptance procedures on September 28, 2026, and the company and EY executed an engagement letter on September 29, 2026.
Benitec Biopharma Inc. (BNTC) dismissed Baker Tilly US, LLP and appointed Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027; EY’s formal engagement remains subject to completion of its client acceptance process. The company said the change followed a review of its auditor engagement as a matter of good corporate governance.
Baker Tilly had served since 2020. Its reports for fiscal years ended June 30, 2025 and 2026 had no adverse opinion or disclaimer and were not qualified or modified as to going concern, uncertainty, audit scope, or accounting principles. The company reported no disagreements with Baker Tilly that, if unresolved, would have required the auditor to refer to them in its report. The only reportable event was a material weakness in controls over share-based compensation calculations, which the company said it remediated as of June 30, 2026.
Benitec Biopharma Inc. (BNTC) has filed a shelf registration statement on Form S-3 to offer, from time to time, up to $200,000,000 of common stock, preferred stock, debt securities, warrants and units. Securities may be sold in one or more series, at prices and on terms set in future prospectus supplements, through underwriters, dealers, agents, or direct sales. Net proceeds are expected to be used for general corporate purposes, including possible debt repayment, capital expenditures, advancing its product pipeline and strategic growth opportunities.
Benitec is a clinical-stage biotechnology company developing BB-301, an AAV-based “silence and replace” gene therapy for Oculopharyngeal Muscular Dystrophy, which has Orphan Drug and Fast Track designations in the U.S. and Orphan status in the EU. This new $200 million shelf is separate from a prior September 2025 S-3 shelf, under which approximately $104 million of common stock has already been issued.
Benitec Biopharma Inc. (BNTC), a clinical-stage gene therapy company focused on its BB-301 “silence and replace” program for oculopharyngeal muscular dystrophy (OPMD), reported higher operating expenses and losses for the fiscal year ended June 30, 2026 while strengthening its cash position via equity financings.
Research and development expenses were $23.4 million and general and administrative expenses were $27.8 million, bringing total operating expenses to $51.2 million, up from $41.8 million in 2025, largely due to higher share-based compensation and payroll. Net loss widened to $45.5 million, though net cash used in operating activities improved to $16.5 million. Benitec ended the year with $180.0 million in cash and cash equivalents, supported by $104.5 million in gross equity proceeds during the year, and estimates this balance will fund operations for at least the next twelve months as it advances the BB-301 Phase 1b/2a trial and prepares for a pivotal study.
Benitec Biopharma Inc. (BNTC) reported higher operating spending and net loss for the year ended June 30, 2026, while highlighting significant clinical and regulatory progress for its lead asset BB-301 in OPMD-related dysphagia.
Total operating expenses rose to $51.2 million from $41.8 million, and net loss attributable to shareholders increased to $45.5 million (or $0.98 per share) from $37.9 million (or $1.05 per share). Cash and cash equivalents grew to $180.0 million, and management characterized the company as well-capitalized. Clinically, all six low-dose Cohort 1 patients completed 12-month follow-up and the three high-dose Cohort 2 patients have been safely treated, with clinically meaningful swallowing improvements reported. A Type C FDA meeting on the BB-301 pivotal study design was held in 3Q 2026, interim data will be presented at ESGCT in October 2026, and Benitec anticipates initiating a pivotal trial in mid-2027.
Benitec Biopharma Inc. director J. Kevin Buchi reported a charitable stock gift. On June 29, 2026, he transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a Section 501(c)(3) charitable organization as a bona fide gift at no stated price. After this transfer, he directly holds 52,097 common shares. This is a non-market, charitable disposition rather than an open-market sale.
Benitec Biopharma Inc. reported changes to its board of directors. On May 22, 2026, the board appointed David Friedman as a Class III director, with a term running until the company’s 2028 annual meeting of stockholders.
In connection with his appointment, Friedman received options to purchase 35,000 shares of common stock under the 2020 Equity and Incentive Compensation Plan, granted on May 26, 2026 at the Nasdaq closing price and vesting in full before the next annual meeting or on the first anniversary of the grant. On the same date, chief financial officer and secretary Megan Boston resigned from the board as part of an ongoing board composition and governance review, but continues in her executive roles, and her departure from the board was not due to any dispute or disagreement with the company.